Provided by Tiger Trade Technology Pte. Ltd.

Nexalin Technology, Inc.

0.3545
+0.00621.78%
Post-market: 0.35500.0005+0.14%18:24 EDT
Volume:91.75K
Turnover:32.63K
Market Cap:7.30M
PE:-0.71
High:0.3754
Open:0.3458
Low:0.3426
Close:0.3483
52wk High:2.31
52wk Low:0.3401
Shares:20.58M
Float Shares:17.86M
Volume Ratio:1.30
T/O Rate:0.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5016
EPS(LYR):-0.5016
ROE:-221.50%
ROA:-118.41%
PB:1.95
PE(LYR):-0.71

Loading ...

Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 Sync™ Neurostimulation Console in Alzheimer’s Disease Program

THOMSON REUTERS
·
Dec 03, 2025

Nexalin Technology Inc: Intends to Incorporate FDA's Feedback From Q-Sub Meeting Into Its Final Pilot Study Protocol

THOMSON REUTERS
·
Dec 03, 2025

Nexalin Technology Hosts Live Investor Webinar Showcasing Mental Health Innovations

Reuters
·
Dec 02, 2025

Nuix (ASX:NXL) delivers shareholders solid 39% CAGR over 3 years, surging 12% in the last week alone

Simply Wall St.
·
Nov 29, 2025

Morgan Stanley Sticks to Their Buy Rating for Nuix Ltd. (NXL)

TIPRANKS
·
Nov 20, 2025

Nexalin 15 mA Neurostimulation Device Shows Promise in Treating Gambling and Alcohol Use Disorders

Reuters
·
Nov 18, 2025

Nexalin Technology Faces Financial Risks Amid U.S.-China Trade Tensions

TIPRANKS
·
Nov 15, 2025

Nexalin Technology Secures Exclusive Distribution Agreement With Carmi Masha in Israel

Reuters
·
Nov 13, 2025

Nuix Limited (ASX:NXL) May Have Run Too Fast Too Soon With Recent 33% Price Plummet

Simply Wall St.
·
Nov 08, 2025

BRIEF-Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by US FDA for the Treatment of Alzheimer’s Disease and Dementia

Reuters
·
Nov 05, 2025

Nexalin Technology Wins Israeli Approval for Gen-2 SYNC Neurostimulation Device

Reuters
·
Oct 30, 2025

Nexalin Technology Announces Regulatory Approval to Sell Gen 2 Sync, 15 Ma Neurostimulation Difs™ Device in Israel

THOMSON REUTERS
·
Oct 30, 2025

Nuix (ASX:NXL) Valuation in Focus Following CEO Transition and Strategic Leadership Changes

Simply Wall St.
·
Oct 29, 2025

Nexalin announces three studies published on Gen-2 Nexalin DIFS technology

TIPRANKS
·
Oct 21, 2025

Nexalin's Difs™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer's and Dementia

THOMSON REUTERS
·
Oct 21, 2025

Nexalin’s Difs™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies

THOMSON REUTERS
·
Oct 21, 2025

Nexalin DIFS Neurostimulation Shows Cognitive Gains in Alzheimer’s Clinical Trials

Reuters
·
Oct 21, 2025

BRIEF-Nexalin Technology enters second amendment to equity distribution agreement - SEC filing

Reuters
·
Oct 16, 2025

Nexalin Technology Inc - Enters Amendment No. 2 to Equity Distribution Agreement - SEC Filing

THOMSON REUTERS
·
Oct 16, 2025

How Investors May Respond To Nuix (ASX:NXL) Integrating AI and Shifting to SaaS Model

Simply Wall St.
·
Oct 12, 2025